CervoMed reported Q1 2026 financials and progress on neflamapimod, a drug targeting dementia with Lewy bodies (DLB). The company finalized a Phase 3 trial design, pending funding, after positive Phase 2b data including MRI evidence of brain improvement and biomarker analyses showing greater benefits in early-stage patients. They also advanced trials in other brain disorders like primary progressive aphasia and ALS. With $12.9 million cash on hand, CervoMed aims to start the Phase 3 DLB trial in the second half of 2026 and expects key data readouts from ongoing studies later this year.
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
